Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and is independently associated with poor cardiovascular outcomes. However, the direct relationship between serum ADMA level and the extent of subclinical coronary atherosclerotic plaque has never been investigated. In total, 130 consecutive asymptomatic Taiwanese subjects (mean age, 55.6±10 years), who received a health screening evaluation, were enrolled. Coronary plaque detected by computed tomography coronary angiography (CTCA) was observed in 85 (65.4%) of 130 individuals. Patients with coronary plaque had a higher ADMA level (1.16±1.15 μmol/L vs. 0.42 ± 0.33 μmol /L, p
|頁（從 - 到）||236-243|
|期刊||Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry|
|出版狀態||已發佈 - 2012|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Immunology and Allergy
Huang, C. Y., Yeh, J. S., Shih, C. M., Lin, F. Y., Kao, Y. T., Tsao, N. W., Hsiao, W. T., Chen, J. W., Chang, N. C., & Shyu, K-G. (2012). The association between serum asymmetric dimethylarginine and coronary atherosclerotic plaque in an asymptomatic population. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 12(3), 236-243.